 | | Vol. 10.34 – 31 August, 2022 |
| |
|
|
| Scientists evaluated whether levels of plasma antigen could predict short-term clinical outcomes and identified clinical and viral factors associated with plasma antigen levels in hospitalized patients with SARS-CoV-2.
[Annals of internal Medicine] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| The authors characterized a human antibody, which they previously isolated from a patient, with a broadly authentic virus-neutralizing activity that inhibited the Delta and Omicron variants with half-maximal inhibitory concentrations of 1.69 ng/ml and 54.31 ng/ml, respectively.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Researchers tested the utility of replication in a vaccine by comparing replication-defective adenovirus and replicating single-cycle adenovirus vaccines that expressed the SARS-CoV-2 spike protein.
[Science Advances] |
|
|
|
| Investigators employed a targeted single-cell RNA sequencing approach to reveal long noncoding RNAs differentially expressed in blood leukocytes during severe COVID-19.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Scientists designed a more universal SARS-CoV-2 DNA vaccine containing receptor binding domain loops from the huCoV-19/WH01, the Alpha, and the Beta variants, combined with the membrane and nucleoproteins.
[EMBO Molecular Medicine] |
|
|
|
| MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
| | The authors assessed the safety, tolerability, and immunogenicity of the PfGAP3KO vaccine and tested its efficacy against controlled human malaria infection in malaria-naïve subjects.
[Science Translational Medicine] |
|
|
|
| Fingolimod was administered to Simian immunodeficiency virus (SIV)-infected rhesus macaques at the initiation of antiretroviral therapy (ART) to block the egress from lymphoid tissues of natural killer and T cells, thereby promoting proximity between cytolytic cells and infected CD4+ T cells.
[Nature Communications] |
|
|
|
| Investigators showed that MvfR promoted intestinal permeability and reported potent anti-MvfR compounds, the N-Aryl Malonamides, resulting from extensive structure-activity-relationship studies and thorough assessment of the inhibition of MvfR-controlled virulence functions.
[Nature Communications] |
|
|
|
| Researchers reported that the primate-specific lncRNA CHROMR was induced by influenza A virus and SARS-CoV-2 infection and coordinated the expression of interferon-stimulated genes that executed antiviral responses.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Scientists used single-cell transcriptomics to construct a genome-wide multistate model of B cell fates upon Epstein-Barr virus infection.
[Cell Reports] |
|
|
|
| Researchers showed that during pneumococcal meningitis, the glymphatic system did not function because of a detachment of the astrocytic end feet from the blood-brain barrier vascular endothelium, which led to misplacement of aquaporin 4 (AQP4) with the consequent loss of the AQP4 water channel’s functionality.
[Microbial Pathogenesis] |
|
|
|
| The authors recovered transcriptome and immune repertoire information for polyclonal T follicular helper cells following lymphocytic choriomeningitis virus infection and B and T cells isolated from the nervous system in the context of experimental autoimmune encephalomyelitis.
[Genes & Immunity] |
|
|
|
|
| Scientists highlight new developments in our understanding of S. epidermidis strain diversity, skin colonization dynamics, and its multifaceted interactions with the host and other members of the skin microbiota.
[Nature Reviews Microbiology] |
|
|
|
| The authors review the intricate interplay between helminth infections and type 2 innate lymphoid cell (ILC2) biology and discuss the host metabolic adaptation to helminth infections and the metabolic pathways fueling ILC2 responses.
[Mucosal Immunology] |
|
|
|
|
| United BioPharma announced that the US FDA has approved a Phase II clinical trial IND submitted by the US National Institute of Allergy and Infectious Diseases (NIAID) of the NIH.
[United BioPharma (Cision US, Inc.)] |
|
|
|
| Kinarus Therapeutics Holding AG announced that the first patient has been dosed in the Phase II KINFAST trial, a multicenter placebo-controlled trial evaluating KIN001 in mild or moderate COVID-19 patients in an outpatient setting.
[Kinarus Therapeutics Holding AG] |
|
|
|
|
|
|
|
| | Genentech, Inc. – South San Francisco, California, United States |
|
|
|
| | Technical University of Denmark – Lyngby, Denmark |
|
|
|
| | STEMCELL Technologies, Inc. – Vancouver, British Columbia, Canada |
|
|
|
| | Melanoma Institute Australia – Sydney, Australia |
|
|
|
| | University of Michigan – Ann Arbor, Michigan, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
